Liarozole fumarate (R85246): In the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 64, Issue 2, 2000, Pages 177-188

  Goss, P E ^a   Strasser, K ^a   Marques, R ^a   Clemons, M ^a   Oza, A ^a   Goel, R ^b   Blackstein, M ^c   Kaizer, L ^d   Sterns, E E ^e   Nabholtz, J M ^f   Coster, R D ^g   Crump, M ^a   Abdolell, M ^a   Qi, S ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d CREDIT VALLEY HOSPITAL   (Canada)

^e KINGSTON GENERAL HOSPITAL   (Canada)

^f CROSS CANCER INSTITUTE   (Canada)

^g JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Aromatase inhibitor; Hormone independent; Liarozole; Metastatic breast cancer; RAMBA

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; LIAROZOLE FUMARATE; TAMOXIFEN; VOROZOLE;

ADULT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRY EYE; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; METASTASIS; NONHUMAN; OVARIECTOMY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; SKIN DISEASE; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; HUMANS; IMIDAZOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE; QUALITY OF LIFE; RATS; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0034546494     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006480504790     Document Type: Article

References (45)

1. Henderson I.C.
2. Multiple endocrine therapy in the management of advanced breast cancer
3. Anastrozole (Arimidex), a potent and selective aromatase inhibitor, vs megestrol acetate (Megace) in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
4. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
5. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
6. Combination chemotherapy compared to tamoxifen as initial therapy for Stage IV breast cancer in elderly women
7. Early clinical experience with liarozole (Liazal™) in patients with progressive prostate cancer
8. Liarozole - A novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyperoterone acetate
9. Liarozole fumarate (R85246): A novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer
10. Phase II study of liarozole in advanced non-small cell lung cancer
11. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: An open study with oral liarozole
12. Oral treatment of ichthyosis by the cytochrome P- 450 inhibitor liarozole
13. R 75251, a new inhibitor of steroid biosynthesis
14. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats
15. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo
16. Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid
17. The Memorial Pain Assessment Card: A valid instrument for the measurement of cancer pain
18. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation
19. Endocrinological effects of single daily ketoconazole therapy in male beagle dogs
20. Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients
21. Dose-responsive induction of mammary gland carcinoma by the intraperitoneal injection of 1-Methyl-1-nitrosourea
22. The rodent uterotrophic assay: Critical protocol features, studies with nonyl phenols, and comparison with a yeast estrogenicity assay
23. Analysis of Repeated Measures
24. Current status of vinorelbine for breast cancer
25. Xeloda in the treatment of metastatic breast cancer
26. Retinoic acid is a negative regulator of AP- 1 responsive genes
27. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP- 1 binding site
28. Binding of retinoids to human breast cancer cell lines and their effects on growth
29. Inhibition of mammary carcinoma growth by retinoidal benzoic acid derivatives
30. Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds
31. Retinoid modulation of estradiol-stimulated growth and of protein synthesis and section in human breast carcinoma cells
32. The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line homonal treatment of advanced breast cancer
33. Xeloda in the treatment of metastatic breast cancer
34. Oral 5-FU analogues in the treatment of breast cancer
35. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
36. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer
37. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
38. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies and implications
39. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients